1. Show article details.

    Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer

    Business Wire – 7:00 AM ET 01/29/2016

    HENDERSON, Nev. “The initiation of the registration trial for SPI-2012 is a significant milestone in the history of our company,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

  2. Show article details.

    Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada

    Business Wire – 7:00 AM ET 01/11/2016

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology and Servier Canada Inc., an affiliate of Servier a research-oriented pharmaceutical company which is pioneering new therapies primarily for cancer and cardiovascular diseases, announce the signing of a strategic partnership.

  3. Show article details.

    Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer

    Business Wire – 7:00 AM ET 12/16/2015

    HENDERSON, Nev. “We are excited to have reached agreement with the FDA on the SPI-2012 SPA, which is the highest priority program at Spectrum,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

  4. Show article details.

    TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers

    Business Wire – 1:23 PM ET 12/15/2015

    On November 17, 2015, TheGrantLawFirm, PLLC disseminated a notice to shareholders under the PSLRA, announcing that it filed a class action complaint on behalf of all securities holders who purchased securities of Spectrum Pharmaceuticals, Inc. (SPPI) during the period between May 7, 2015 until October 23, 2015, inclusive.

  5. Show article details.

    Marqibo® Made Available to Acute Lymphoblastic Leukemia Patients Through Global myTomorrows Platform

    PR Newswire – 8:30 AM ET 12/10/2015

    AMSTERDAM, December 10, 2015 myTomorrows, announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (SPPI) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.      In August 2012, the US FDA approved the product for treatment of this rare type of leukemia.

  6. Show article details.

    Spectrum Pharmaceuticals Highlights Four Abstracts on SPI-2012 and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS)

    Business Wire – 7:00 AM ET 12/08/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the San Antonio Breast Cancer Symposium, being held in San Antonio, Texas, from December 8-12, 2015.

  7. Show article details.

    BRIEF-Spectrum Pharmaceuticals and Onxeo announce Phase 1 trial results of Belinostat with CHOP

    Reuters – 2:29 AM ET 12/07/2015

    Onxeo SA and Spectrum Pharmaceuticals (SPPI) : * Reported on Sunday complete response in 67 pct of patients with peripheral T-cell lymphoma in combination of Belinostat and standard CHOP. * Study shows 86 pct objective response rate with 67 pct complete responses in newly diagnosed patients with Peripheral T-cell Lymphoma. * At full dose intensity the belinostat-chop combination was well-tolerated.

  8. Show article details.

    Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq®) and Standard CHOP

    Business Wire – 12:00 PM ET 12/06/2015

    HENDERSON, Nev. The results were presented today in an oral presentation at the 57th American Society of Hematology Annual Meeting & Exposition by Dr. Patrick Johnston, MD, PhD, Assistant Professor of Medicine at the Mayo Clinic, Rochester, MN, USA.

  9. Show article details.

    Spectrum Pharmaceuticals Highlights 18 Abstracts at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015

    Business Wire – 7:00 AM ET 12/04/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the 57th Annual Meeting of the American Society of Hematology, being held in Orlando, Florida, from December 5-8, 2015.

  10. Show article details.

    Investor Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 From Investment in Spectrum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – SPPI

    GlobeNewswire – 6:24 PM ET 12/03/2015

    The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Spectrum Pharmaceuticals, Inc. (SPPI) securities during the period between May 7, 2015 and October 23, 2015, inclusive.

  11. Show article details.

    Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug (IND) Application for Poziotinib

    Business Wire – 7:00 AM ET 11/20/2015

    HENDERSON, Nev. “This Phase 2 study is an important step for us to solidify our registration strategy in the U.S.,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

  12. Show article details.

    Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma

    Business Wire – 3:00 AM ET 11/18/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the divestment of ZEVALIN rights in Japan and other countries in Asia Pacific, Middle East, Africa and Latin America, to Mundipharma.

  13. Show article details.

    TheGrantLawFirm, PLLC Files Class Action on Behalf of Spectrum Pharmaceuticals, Inc. Securities Purchasers

    Business Wire – 12:11 PM ET 11/17/2015

    TheGrantLawFirm, PLLC announces that it filed a class action complaint on behalf of all securities holders who purchased the securities of Spectrum Pharmaceuticals, Inc. (SPPI) during the period between May 7, 2015 until October 23, 2015, inclusive.

  14. Show article details.

    INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Spectrum Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit

    Business Wire – 6:17 PM ET 11/12/2015

    The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Spectrum Pharmaceuticals, Inc. (SPPI) securities during the period between May 7, 2015 and October 23, 2015, inclusive.

Page:

Today's and Upcoming Events

  • Mar
    11

    SPPI to announce Q4 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.